print-icon
print-icon

Time To Buy Biotech

Portfolio Armor's Photo
by Portfolio Armor
Tuesday, Dec 16, 2025 - 23:32

 

Bull Scientist

From Moonshot to FDA Rug Pull—and Back Again?

In late September, uniQure (QURE) became one of the most explosive biotech stories of the year.

Following updated data around AMT-130, its gene therapy candidate for Huntington’s Disease, the stock went nearly vertical. Over the span of a few weeks, QURE surged from the low-$20s into the mid-$50s, more than doubling as investors began to price in the possibility of the first effective disease-modifying treatment for Huntington’s.

The excitement wasn’t limited to retail traders.

On September 24, Martin Shkreli weighed in publicly, arguing that if AMT-130 ultimately worked, QURE could be a 5× to 10× stock from those levels — a claim that, at the time, didn’t sound outrageous given the size of the unmet medical need and the absence of competing therapies.

Then came November.

The FDA Rug Pull

In mid-November, the FDA rejected uniQure’s plan to rely on external control data—a form of real-world evidence—as part of its regulatory pathway.

The market’s interpretation was swift and brutal.

Without that pathway, investors were suddenly forced to assume the possibility of a new, multi-year Phase 3 trial, with costs likely north of $100 million and years of additional uncertainty. Within days, QURE collapsed from the $50s back into the low-$20s, wiping out more than half of its market value almost overnight.

Shkreli claimed he had sold QURE. 

This wasn’t a normal pullback.

The stock was repriced for failure.

What Changed On Monday

On December 15, the FDA released new guidance that directly addressed the issue that crushed QURE last month.

In plain English—the agency eliminated the requirement for identifiable individual patient data in certain real-world evidence submissions, the exact constraint that invalidated uniQure’s approach in November.

This wasn’t a reinterpretation by analysts.
It wasn’t a rumor.
It was a formal change in FDA guidance.

In regulatory terms, this is about as close as you get to the rules of the game being rewritten after the market has already moved on.

Does this guarantee approval for AMT-130? No.

But it materially reopens a pathway that investors had just assumed was closed — after the stock had already been punished accordingly.

Why This Setup Matters

Biotech stocks don’t move in smooth increments. They move when:

  • regulatory probabilities change,

  • narratives flip,

  • and positioning is caught leaning the wrong way.

QURE now sits in a familiar but powerful setup:

  • a stock that already completed a full hope → despair cycle,

  • after losing 50%+ of its value,

  • just as the regulatory assumption that drove the collapse has been reversed.

Those are exactly the conditions under which violent repricings tend to occur.

What We Did About It

We sent out a trade alert Tuesday built specifically around this development.

Our structure is designed to:

  • keep downside defined,

  • leave upside uncapped, and

  • avoid the need to babysit a highly volatile biotech.

We also paired it with a picks-and-shovels play tied to the same therapeutic ecosystem—another name that was hit hard in November for largely the same reason. That picks & shovels play closed up nearly 12%.

If you'd like a heads up when we send out our next trade alert, you can subscribe to The Portfolio Armor Substack below. 

 

And if you think we're wrong, you can hedge against us here or here. 

 

For now, one thing is clear: uniQure’s story isn’t over; this week, the FDA quietly made that possible again.

Contributor posts published on Zero Hedge do not necessarily represent the views and opinions of Zero Hedge, and are not selected, edited or screened by Zero Hedge editors.
Loading...